alabdy
07-19-2022, 04:08 AM
When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.
But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.
What is the story behind this new drug?
Guest: Pam Belluck (https://www.nytimes.com/by/pam-belluck?smid=pc-thedaily), a health and science writer for The New York Times.
Sign up here (https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily) to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter (https://www.nytimes.com/newsletters/the-daily?module=inline).
Background reading:
Aduhelm, also known as aducanumab (https://www.nytimes.com/2021/06/08/business/aducanumab-alzheimers-cost.html), was approved despite opposition from the F.D.A.’s independent advisory committee (https://www.nytimes.com/2021/06/07/health/aduhelm-fda-alzheimers-drug.html) and some Alzheimer’s experts.
Even those who supported the F.D.A.’s approval have said that authorizing it for anyone with the disease is much too broad (https://www.nytimes.com/2021/06/21/health/aduhelm-alzheimers-drug.html).
For more information on today’s episode, visit nytimes.com/thedaily (http://nytimes.com/thedaily?smid=pc-thedaily). Transcripts of each episode will be made available by the next workday.
أكثر... (https://www.nytimes.com/the-daily)
But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.
What is the story behind this new drug?
Guest: Pam Belluck (https://www.nytimes.com/by/pam-belluck?smid=pc-thedaily), a health and science writer for The New York Times.
Sign up here (https://www.nytimes.com/newsletters/signup/NTTD?smid=pc-thedaily) to get The Daily in your inbox each morning. And for an exclusive look at how the biggest stories on our show come together, subscribe to our newsletter (https://www.nytimes.com/newsletters/the-daily?module=inline).
Background reading:
Aduhelm, also known as aducanumab (https://www.nytimes.com/2021/06/08/business/aducanumab-alzheimers-cost.html), was approved despite opposition from the F.D.A.’s independent advisory committee (https://www.nytimes.com/2021/06/07/health/aduhelm-fda-alzheimers-drug.html) and some Alzheimer’s experts.
Even those who supported the F.D.A.’s approval have said that authorizing it for anyone with the disease is much too broad (https://www.nytimes.com/2021/06/21/health/aduhelm-alzheimers-drug.html).
For more information on today’s episode, visit nytimes.com/thedaily (http://nytimes.com/thedaily?smid=pc-thedaily). Transcripts of each episode will be made available by the next workday.
أكثر... (https://www.nytimes.com/the-daily)